Dirk Schadendorf
Impact in
- Oncology top 0.01%
- Cancer Immunotherapy and Biomarkers
- CAR-T cell therapy research
- Cutaneous Melanoma Detection and Management
- Immunology top 0.01%
- Immunotherapy and Immune Responses
- Immune Cell Function and Interaction
Papers in
- Oncology 616
- Cutaneous Melanoma Detection and Management 267
- Cancer Immunotherapy and Biomarkers 197
- CAR-T cell therapy research 155
- Immunology 278
- Immunotherapy and Immune Responses 216
- T-cell and B-cell Immunology 51
- Co-authors
- Reinhard Dummer (102 shared papers)Caroline Robert (78 shared papers)Axel Hauschild (108 shared papers)Antje Sucker (98 shared papers)Selma Ugurel (109 shared papers)Claus Garbe (70 shared papers)Jedd D. Wolchok (20 shared papers)Frank Stephen Hodi (31 shared papers)
- Journals
- European Journal of Cancer (143 papers)Annals of Oncology (94 papers)Journal of Clinical Oncology (46 papers)Clinical Cancer Research (33 papers)International Journal of Cancer (33 papers)
- Partner nations
- GermanyUnited StatesFrance
In The Last Decade
Dirk Schadendorf
1.2k papers receiving 164.4k citations
Dirk Schadendorf's Hit Papers
Peers
Comparison fields: 5 of 210
- Oncology 87.4k
- Immunology 40.3k
- Cancer Research 21.6k
- Molecular Biology 65.6k
- Pulmonary and Respiratory Medicine 17.7k
Countries citing papers authored by Dirk Schadendorf
This map shows the geographic impact of Dirk Schadendorf's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Dirk Schadendorf with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Dirk Schadendorf more than expected).
Fields of papers citing papers by Dirk Schadendorf
This network shows the impact of papers produced by Dirk Schadendorf. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Dirk Schadendorf. The network helps show where Dirk Schadendorf may publish in the future.
Co-authors
The 25 scholars most cited alongside Dirk Schadendorf, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 1.2k papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Improved Survival with Ipilimumab in Patients with Metastatic Melanoma Hit paper breakdown → | 2010 | 12635 |
| 2 | Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma Hit paper breakdown → | 2015 | 6916 |
| 3 | Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation Hit paper breakdown → | 2011 | 6388 |
| 4 | Nivolumab in Previously Untreated Melanoma without BRAF Mutation Hit paper breakdown → | 2014 | 4679 |
| 5 | Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma Hit paper breakdown → | 2017 | 4597 |
| 6 | Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma Hit paper breakdown → | 2019 | 2848 |
| 7 | An Integrated TCGA Pan-Cancer Clinical Data Resource to Drive High-Quality Survival Outcome Analytics Hit paper breakdown → | 2018 | 2602 |
| 8 | Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade Hit paper breakdown → | 2016 | 2528 |
| 9 | Genomic Classification of Cutaneous Melanoma Hit paper breakdown → | 2015 | 2509 |
| 10 | Vaccination of melanoma patients with peptide- or tumorlysate-pulsed dendritic cells Hit paper breakdown → | 1998 | 2486 |
| 11 | The repertoire of mutational signatures in human cancer Hit paper breakdown → | 2020 | 2339 |
| 12 | Oncogenic Signaling Pathways in The Cancer Genome Atlas Hit paper breakdown → | 2018 | 2334 |
| 13 | Genomic correlates of response to CTLA-4 blockade in metastatic melanoma Hit paper breakdown → | 2015 | 2275 |
| 14 | Improved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib Hit paper breakdown → | 2014 | 2163 |
| 15 | A Landscape of Driver Mutations in Melanoma Hit paper breakdown → | 2012 | 2138 |
| 16 | Pan-cancer analysis of whole genomes Hit paper breakdown → | 2020 | 2109 |
| 17 | Improved Survival with MEK Inhibition in BRAF-Mutated Melanoma Hit paper breakdown → | 2012 | 1820 |
| 18 | Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma Hit paper breakdown → | 2015 | 1734 |
| 19 | Tertiary lymphoid structures improve immunotherapy and survival in melanoma Hit paper breakdown → | 2020 | 1726 |
| 20 | Cell-of-Origin Patterns Dominate the Molecular Classification of 10,000 Tumors from 33 Types of Cancer Hit paper breakdown → | 2018 | 1720 |
About Dirk Schadendorf
Dirk Schadendorf is a scholar working on Oncology, Immunology, Molecular Biology, Dermatology and Cancer Research, having authored 1.2k papers that have together received 167.9k indexed citations. Recurring topics across this work include Melanoma and MAPK Pathways (287 papers), Cutaneous Melanoma Detection and Management (267 papers), Immunotherapy and Immune Responses (216 papers), Cancer Immunotherapy and Biomarkers (197 papers), CAR-T cell therapy research (155 papers), Cancer Genomics and Diagnostics (66 papers), Nonmelanoma Skin Cancer Studies (60 papers) and T-cell and B-cell Immunology (51 papers). The work is most often cited by research in Oncology (87.4k citations), Immunology (40.3k citations), Cancer Research (21.6k citations), Molecular Biology (65.6k citations) and Pulmonary and Respiratory Medicine (17.7k citations). Dirk Schadendorf has collaborated with scholars based in Germany, United States and France. Frequent co-authors include Reinhard Dummer, Caroline Robert, Axel Hauschild, Antje Sucker, Selma Ugurel, Claus Garbe, Jedd D. Wolchok, Frank Stephen Hodi, Yuansheng Sun and Selma Alijagic. Their work appears in journals such as European Journal of Cancer, Annals of Oncology, Journal of Clinical Oncology, Clinical Cancer Research and International Journal of Cancer.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.